The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial

Tuberculosis: novel vaccine formulation elicits strong immune responses A tuberculosis vaccine containing an immunity-potentiating agent stimulated strong immune responses in a first-in-human trial. Tuberculosis (TB) is the world’s foremost cause of infectious disease deaths, yet lacks an effective...

Full description

Bibliographic Details
Main Authors: Rhea N. Coler, Tracey A. Day, Ruth Ellis, Franco M. Piazza, Anna Marie Beckmann, Julie Vergara, Tom Rolf, Lenette Lu, Galit Alter, David Hokey, Lakshmi Jayashankar, Robert Walker, Margaret Ann Snowden, Tom Evans, Ann Ginsberg, Steven G. Reed, The TBVPX-113 Study Team
Format: Article
Language:English
Published: Nature Publishing Group 2018-09-01
Series:npj Vaccines
Online Access:http://link.springer.com/article/10.1038/s41541-018-0057-5